MedComm – Oncology最新文献_第7页

Gene LY96 is an M2 macrophage-related biomarker and is associated with immunosuppression in renal cell carcinoma LY96基因是M2巨噬细胞相关的生物标志物，与肾细胞癌的免疫抑制有关

MedComm – Oncology Pub Date : 2023-09-14 DOI: 10.1002/mog2.52

Weiquan Li, Xiangui Meng, Tiexi Yu, Xin Shi, Wei Dong, Hailong Ruan, Tao Wang, Wen Xiao

{"title":"Gene LY96 is an M2 macrophage-related biomarker and is associated with immunosuppression in renal cell carcinoma","authors":"Weiquan Li, Xiangui Meng, Tiexi Yu, Xin Shi, Wei Dong, Hailong Ruan, Tao Wang, Wen Xiao","doi":"10.1002/mog2.52","DOIUrl":"https://doi.org/10.1002/mog2.52","url":null,"abstract":"Lymphocyte Antigen 96 (LY96) was identified as an oncogene in several tumors. However, its role in renal cancer has not been explored. In the study, LY96 is identified abnormally expressed using several public kidney cancer sequencing data. The expression level of LY96 is validated using paired clinical samples. Survival analyses and ROC curves are used to examine its prognostic and diagnostic value. Gene sets enrichment analyses (GSEA) show LY96 might influence immune processes. Then immune infiltration analyses results suggest that LY96 is positively correlated with M2 macrophages infiltration in RCC. Single-cell data are used to verify its association with macrophages. Moreover, LY96 is positively with various immune scores and might affect the efficacy of immunotherapy. Drug screening results show LY96 might be the target of vemurafenib and etoposide. Further experiments confirm the spatial co-localization of LY96 and M2, and knocking down LY96 can inhibit M2 polarization. Cell viability experiments indicate that knocking down LY96 would result in a decrease in the resistance of M2 macrophages to etoposide. The study shows LY96 could act as an unfavorable biomarker for RCC and possibly contribute to cancer progression by promoting the infiltration of M2 macrophage. LY96 could be a novel therapeutic target for RCC.","PeriodicalId":100902,"journal":{"name":"MedComm – Oncology","volume":"2 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/mog2.52","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50133532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Novel DNA methylation biomarkers in enhancer regions with chromatin interactions for diagnosis of non-small-cell lung cancer 染色质相互作用增强子区新的DNA甲基化生物标志物用于诊断非小细胞肺癌癌症

MedComm – Oncology Pub Date : 2023-09-12 DOI: 10.1002/mog2.51

Zhixian Zhu, Qiangwei Zhou, Pengpeng Guan, Yuanhui Sun, Guoliang Li

{"title":"Novel DNA methylation biomarkers in enhancer regions with chromatin interactions for diagnosis of non-small-cell lung cancer","authors":"Zhixian Zhu, Qiangwei Zhou, Pengpeng Guan, Yuanhui Sun, Guoliang Li","doi":"10.1002/mog2.51","DOIUrl":"https://doi.org/10.1002/mog2.51","url":null,"abstract":"Lung cancer is the leading cause of cancer‐related deaths worldwide. DNA methylation has been recognized as a potential biomarker for lung cancer diagnosis. Most reported DNA methylation biomarkers focus on promoter regions, leaving enhancer regions largely unexplored. Here, we employed multiomics data to identify DNA methylation biomarkers for non‐small‐cell lung cancer diagnosis. Especially, we linked enhancers to their target genes using long‐range chromatin interactions for biomarker prediction. We discovered two sets of DNA methylation biomarkers: one in promoter regions and another in enhancer regions. Both achieved extremely high sensitivity and specificity in five independent validation data sets. Compared with three other reported biomarker sets, both groups in our study demonstrated better and more robust classification performance in validation data sets. These novel DNA methylation biomarkers may improve lung cancer screening and ultimately contribute to improved clinical outcomes for patients. To our best knowledge, this is the first time to introduce chromatin interactions to link enhancers to their targets for biomarker study, highlighting the potential of enhancer methylation as a complement to current promoter‐based DNA methylation biomarkers. Our approach may have potential applications for other cancer types and could be a valuable direction for future research in the field of cancer biomarker discovery.","PeriodicalId":100902,"journal":{"name":"MedComm – Oncology","volume":"2 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/mog2.51","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50131040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Applications of macrocyclic molecules in cancer therapy: Target cancer development or overcome drug resistance 大环分子在癌症治疗中的应用：靶向癌症发展或克服耐药性

MedComm – Oncology Pub Date : 2023-09-04 DOI: 10.1002/mog2.50

Xiaoling Song, Yifan Wu, Xiaojuan Qu, Biao Jiang

{"title":"Applications of macrocyclic molecules in cancer therapy: Target cancer development or overcome drug resistance","authors":"Xiaoling Song, Yifan Wu, Xiaojuan Qu, Biao Jiang","doi":"10.1002/mog2.50","DOIUrl":"https://doi.org/10.1002/mog2.50","url":null,"abstract":"Cancer is a worldwide leading cause of cancer-related death due to a lack of efficient disease control by drugs. With the increasing unmet needs in cancer treatment, developing novel effective cancer drugs is in great demand. Macrocyclic molecules represent a group of drug molecules with a cyclic skeleton which endows them with unique drug properties such as improved bioavailability, enhanced metabolic stability, increased binding affinity, and favorable pharmacokinetics parameters. The Food and Drug Administration (FDA) has approved a bunch of macrocyclic drugs to treat cancer patients. However, the importance of such molecules in cancer drug development remains underestimated. Recent studies support that macrocyclic molecules can also serve as an effective strategy to overcome drug resistance in cancer treatment, but is a lack of review. The purpose of this manuscript was to provide shreds of evidence on the applications of macrocyclic molecules for cancer therapy: (1) act as cancer drugs to target different proteins critical for cancer development; (2) act as cancer drugs to target resistant mutants of oncogenes to overcome drug resistance in targeted therapy. This review will help to attract more interest in developing macrocyclic drugs for cancer therapy and potentially provide more novel strategies to benefit cancer patients and society.","PeriodicalId":100902,"journal":{"name":"MedComm – Oncology","volume":"2 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/mog2.50","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50121208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Big data and single-cell sequencing in acute myeloid leukemia research 大数据和单细胞测序在急性粒细胞白血病研究中的应用

MedComm – Oncology Pub Date : 2023-08-28 DOI: 10.1002/mog2.47

Yuxuan Zou, Huiyuan Zhang, Hongbo Hu

{"title":"Big data and single-cell sequencing in acute myeloid leukemia research","authors":"Yuxuan Zou, Huiyuan Zhang, Hongbo Hu","doi":"10.1002/mog2.47","DOIUrl":"https://doi.org/10.1002/mog2.47","url":null,"abstract":"The advancement of diverse technologies has led to a substantial increase in valuable biomedical data, particularly in the field of acute myeloid leukemia (AML). Effective utilization of this wealth of data is crucial for attaining a comprehensive and in-depth understanding of AML, thereby facilitating optimal diagnosis, treatment, and prognosis. Among the various approaches to data acquisition, single-cell sequencing has emerged as an impressive tool. The developments of single-cell sequencing methods have empowered researchers to analyze the genome, transcriptome, proteome, and epigenome data at the single-cell level. It also offers a means to uncover fine information, providing unique prognostic insights and aiding in the identification of therapeutic targets. Furthermore, it enhances our understanding of AML heterogeneity, clonal evolution, and resistance mechanisms, ultimately leading to the development of better treatment strategies. In this review, we present an overview of AML as well as single-cell sequencing technologies, then explore their potential contributions to AML research in different aspects, and provide some information about resources and data processing.","PeriodicalId":100902,"journal":{"name":"MedComm – Oncology","volume":"2 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/mog2.47","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50146476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

cGAS-STING signaling in cancer: Regulation and therapeutic targeting 癌症中的cGAS-STING信号：调节和治疗靶向

MedComm – Oncology Pub Date : 2023-08-21 DOI: 10.1002/mog2.49

Xinzou Fan, Xiaoshuang Song, Wenjing Chen, Hantian Liang, Hiroko Nakatsukasa, Dunfang Zhang

{"title":"cGAS-STING signaling in cancer: Regulation and therapeutic targeting","authors":"Xinzou Fan, Xiaoshuang Song, Wenjing Chen, Hantian Liang, Hiroko Nakatsukasa, Dunfang Zhang","doi":"10.1002/mog2.49","DOIUrl":"https://doi.org/10.1002/mog2.49","url":null,"abstract":"Immunotherapy has revolutionized antitumor therapy. Since the discovery of stimulators of interferon genes (STING), efforts have been made to elucidate their mechanisms and physiological functions and explore the potential of STING as a therapeutic target in immune-related diseases and malignant tumors. In recent years, STING agonists have become a popular research topic. Activation of the cyclic GMP–AMP synthase (cGAS)-STING pathway produces large amounts of type I interferons, which play key roles in activating innate and acquired immune responses. The cGAS-STING pathway influences almost all aspects of tumorigenesis and has great antitumor potential. In addition, the activation of the cGAS-STING pathway is associated with tumor regression, prolonged survival of patients with cancer, and enhanced immunotherapy. Given the positive role of STING in antitumor immunity, the development of STING-targeted drugs is important. In this review, we summarize the activation and potential mechanisms of the cGAS-STING pathway, discuss the association of the cGAS-STING pathway with tumors and autoimmune diseases, and highlight research progress, clinical applications, and combination drug strategies for STING agonists.","PeriodicalId":100902,"journal":{"name":"MedComm – Oncology","volume":"2 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/mog2.49","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50139724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Microtubule-targeting agents for cancer treatment: Seven binding sites and three strategies 用于癌症治疗的微管靶向剂：七个结合位点和三种策略

MedComm – Oncology Pub Date : 2023-08-16 DOI: 10.1002/mog2.46

Xingyu Wang, Benoît Gigant, Xi Zheng, Qiang Chen

{"title":"Microtubule-targeting agents for cancer treatment: Seven binding sites and three strategies","authors":"Xingyu Wang, Benoît Gigant, Xi Zheng, Qiang Chen","doi":"10.1002/mog2.46","DOIUrl":"https://doi.org/10.1002/mog2.46","url":null,"abstract":"Microtubules are pivotal in diverse cellular functions encompassing cell signaling, morphology, intracellular trafficking, and cell mitosis/division. They are validated targets for disease treatment, notably hematological cancers and solid tumors. Microtubule-targeting agents (MTAs) exert their effects by modulating microtubule dynamics, impeding cell proliferation, and promoting cell death. Recent advances in structural biology have unveiled novel perspectives for investigating multiple binding sites and mechanisms of action used by MTAs. In this review, we first provide an overview of the intricate structure and dynamics of microtubules. Then we explore the seven binding sites and the three primary strategies (stabilization, destabilization, and degradation) harnessed by MTAs. Furthermore, we introduce the emerging domain of microtubule-targeting degraders, exemplified by PROteolysis TArgeting Chimeras and small-molecule degraders, which enable precise degradation of specific microtubule-associated proteins implicated in cancer pathogenesis. Additionally, we discuss the promising realm of precision-targeted approaches, including antibody–drug conjugates and the utilization of photopharmacology in MTAs. Lastly, we provide a comprehensive overview of the clinical applications of microtubule-targeting therapies, assessing their efficacy and current challenges. We aim to provide a global picture of MTAs development as well as insights into the microtubule-targeting drug discovery for cancer treatment.","PeriodicalId":100902,"journal":{"name":"MedComm – Oncology","volume":"2 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/mog2.46","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50143014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison of Billroth II with Braun and Roux-en-Y reconstructions after distal gastrectomy for gastric cancer: A meta-analysis 癌症远端胃切除术后Billroth II与Braun和Roux-en-Y重建术的比较：荟萃分析

MedComm – Oncology Pub Date : 2023-08-09 DOI: 10.1002/mog2.48

Defei Chen, Chenglin Tang, Fan He, Fuyu Yang, Saed Woraikat, Kun Qian

{"title":"Comparison of Billroth II with Braun and Roux-en-Y reconstructions after distal gastrectomy for gastric cancer: A meta-analysis","authors":"Defei Chen, Chenglin Tang, Fan He, Fuyu Yang, Saed Woraikat, Kun Qian","doi":"10.1002/mog2.48","DOIUrl":"https://doi.org/10.1002/mog2.48","url":null,"abstract":"Roux-en-Y (RY) and Billroth II with Braun (BB) reconstruction are two similar methods of reconstruction after distal gastrectomy (DG). Currently, it is unclear which method is superior. This meta-analysis was performed to compare the safety and efficacy of BB and RY reconstruction after DG for gastric cancer. A literature search of Pubmed, Embase, Web of Science, and Cochrane Library was conducted to identify studies comparing BB with RY after DG for gastric cancer until the end of October 2022. Main outcomes assessed were perioperative outcomes, postoperative complications, functional findings, and nutritional status. Meta-analyses were performed using RevMan 5.4 software. Finally, eight studies with a total of 910 patients were considered for the meta-analysis. The meta-analysis results revealed that operation time, anastomosis time, incidence of total complications, and delayed gastric emptying were reduced, and the incidence of bile reflux was increased in patients undergoing BB compared to RY reconstruction. In conclusion, BB has the advantage of reducing operative time, anastomotic time, intraoperative blood loss, overall postoperative complications, and delayed gastric emptying. RY has the advantage of preventing bile reflux and gastritis after surgery.","PeriodicalId":100902,"journal":{"name":"MedComm – Oncology","volume":"2 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/mog2.48","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50142080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Extracorporeal bladder vibration assay enables early detection and recurrence monitoring for bladder cancer 体外膀胱振动检测可实现癌症的早期检测和复发监测

MedComm – Oncology Pub Date : 2023-07-23 DOI: 10.1002/mog2.45

Junqi Cui, Xia Wang, Jiali Lin, Yun Zou, Hongkang Wang, Wenyan Jiang, Jiajia Chen, Yamin Rao, Bin Xu, Long Li

{"title":"Extracorporeal bladder vibration assay enables early detection and recurrence monitoring for bladder cancer","authors":"Junqi Cui, Xia Wang, Jiali Lin, Yun Zou, Hongkang Wang, Wenyan Jiang, Jiajia Chen, Yamin Rao, Bin Xu, Long Li","doi":"10.1002/mog2.45","DOIUrl":"https://doi.org/10.1002/mog2.45","url":null,"abstract":"Cystoscopy is the current gold standard for diagnosing bladder cancer (Bca), but its invasive nature often results in patient discomfort. This study aims to debise a new strategy to enhance BCa detection. We collected data from 30 BCa patients between January and June 2022. We obtained spontaneously voided urine specimens from these patients before and after administering extracorporeal bladder vibration. These specimens underwent routine cytologic examination and fluorescence in situ hybridization (FISH). Furthermore, we conducted a follow-up 3 months postoperation. We recollected urine specimens before and after extracorporeal bladder vibration, repeating the cytologic examination and FISH. Our findings indicated an increase in the number of exfoliated cells in patients' urine postvibration compared to previbration. The liquid-based cell staining results showed an increased detection rate of abnormal cells in the urinary sediment of patients with both low and high-grade urothelial carcinoma postvibration. Similarly, the FISH results revealed an increased detection rate of CEP3 and CEP7 positive cells postvibration. Additionally, 3 months postoperation, we found abnormal cells in the urine of one patient previbration and in three patients postvibration. Further cystoscopic biopsy confirmed that these three patients had developed tumor recurrence. Our study substantiates that the extracorporeal bladder vibration assay significantly enhances BCa detection and the prediction of tumor recurrence. This method is simple, quick, and cost-effective, making it a promising approach worthy of widespread clinical application.","PeriodicalId":100902,"journal":{"name":"MedComm – Oncology","volume":"2 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/mog2.45","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50153629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

PTK2 promotes uveal melanoma metastasis by activating epithelial-to-mesenchymal transition PTK2通过激活上皮-间质转化促进葡萄膜黑色素瘤转移

MedComm – Oncology Pub Date : 2023-07-18 DOI: 10.1002/mog2.44

Pu Luo, Jingjing Duan, Qiong Chen, Ling Shao, Wen Xiao, Xunqi Liu, Gengwei Zhang, Xiaohua Tan, Zhongyi Fan

{"title":"PTK2 promotes uveal melanoma metastasis by activating epithelial-to-mesenchymal transition","authors":"Pu Luo, Jingjing Duan, Qiong Chen, Ling Shao, Wen Xiao, Xunqi Liu, Gengwei Zhang, Xiaohua Tan, Zhongyi Fan","doi":"10.1002/mog2.44","DOIUrl":"https://doi.org/10.1002/mog2.44","url":null,"abstract":"Uveal melanoma (UM) is the most common primary intraocular malignant tumor in adults. More than half of UM cases develop distant metastasis to the liver, lung, bone, and other organs, which frequently results in patient death. However, the mechanisms underlying UM metastasis remain largely unknown. Here, we report that protein tyrosine kinase 2 (PTK2), a nonreceptor protein tyrosine kinase also known as focal adhesion kinase (FAK), was overexpressed in most examined UM specimens. Furthermore, we identified PTK2 expression as a novel independent risk factor that predicts poor prognosis of UM patients. Mechanistic studies revealed that PTK2 promotes the EMT phenotype, leading to metastasis of UM cells. We showed that PTK2, located on chromosome 8q, is a functional gene of chromosome 8q gain to UM metastasis, which may represent the molecular mechanism for the aberrant expression and activation of PTK2 in UM. Our data reveal a novel role and mechanism of PTK2 in the metastatic process of UM, suggesting PTK2 may be a potential prognostic biomarker for UM metastasis and a promising therapeutic target for UM treatment.","PeriodicalId":100902,"journal":{"name":"MedComm – Oncology","volume":"2 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/mog2.44","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50136893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association of m1A modification gene polymorphisms with glioma risk in Chinese children m1A修饰基因多态性与中国儿童脑胶质瘤风险的关系

MedComm – Oncology Pub Date : 2023-07-16 DOI: 10.1002/mog2.43

Fan Liao, Rui-Xi Hua, Xingyu Jia, Yuxiang Liao, Li Yuan, Jichen Ruan, Tianfeng Li, Zhenjian Zhuo, Jing He

{"title":"Association of m1A modification gene polymorphisms with glioma risk in Chinese children","authors":"Fan Liao, Rui-Xi Hua, Xingyu Jia, Yuxiang Liao, Li Yuan, Jichen Ruan, Tianfeng Li, Zhenjian Zhuo, Jing He","doi":"10.1002/mog2.43","DOIUrl":"https://doi.org/10.1002/mog2.43","url":null,"abstract":"Glioma is a highly heterogeneous malignancy with a high mortality rate and poor prognosis. m1A methylation modifications are associated with gliomagenesis. However, whether single nucleotide polymorphisms (SNPs) of m1A modification genes are associated with glioma risk is unclear. We successfully genotyped 20 SNPs of m1A-modified genes TRMT10C, TRMT61B, TRMT6, TRM61, ALKBH1, YTHDC1, YTHDF1, and YTHDF2 in 314 pediatric glioma patients and 380 cancer-free controls using TaqMan probes. Associations of polymorphisms with glioma risk were assessed by the odds ratios and 95% confidence intervals generated by logistic regression models. Stratified analysis was performed by age, gender, tumor subtype, and clinical stage. The results showed that TRMT10C rs2303476, TRMT10C rs4257518, TRM61 rs2296484, and YTHDF2 rs3738067 polymorphisms were significantly associated with an increased risk of glioma, TRMT61B rs4563180, YTHDC1 rs2293595, and YTHDC1 rs3813832 polymorphisms were significantly associated with a reduced risk of glioma. In addition, analysis of the expression quantitative trait loci-showed that the TRM61 rs2296484 T allele significantly increased TRM61 messenger RNA (mRNA) expression, the YTHDF2 rs3738067 G allele significantly increased YTHDF2 mRNA expression, and the TRMT61B rs4563180 C allele significantly decreased TRMT61B mRNA expression. Overall, we identified several promising candidates for m1A modification gene polymorphisms as biomarkers of glioma risk.","PeriodicalId":100902,"journal":{"name":"MedComm – Oncology","volume":"2 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/mog2.43","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50134566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0